Bioequivalence of a single dose of two palbociclib formulations in healthy Chinese subjects under fasting conditions: a two-period crossover study with rabeprazole pre-treatment
Authors
Bo Qiu (ORCID: https://orcid.org/0000-0001-8469-4246)
Shuo Shi (ORCID: https://orcid.org/0000-0003-4387-3445)
Liangjia Bi (ORCID: https://orcid.org/0000-0001-8635-427X)
Wanjun Bai (ORCID: https://orcid.org/0009-0008-3266-8765)
Jin Gao
Zhang Xueyuan
Caihui Guo
Huizhen Wu
Haojing Song
Yin Deliang
Yiting Hu (ORCID: https://orcid.org/0000-0001-8538-0337)
Bioequivalence of a single dose of two palbociclib formulations in healthy Chinese subjects under fasting conditions: a two-period crossover study with rabeprazole pre-treatment
Bo Qiu, Shuo Shi, Liangjia Bi, Wanjun Bai et al.
Journal
Frontiers in Pharmacology
Topics
Advanced Breast Cancer Therapies
article
Bioequivalence of a single dose of two palbociclib formulations in healthy Chinese subjects under fasting conditions: a two-period crossover study with rabeprazole pre-treatment
Hebei Medical University (CN), Shanghai Innovative Research Center of Traditional Chinese Medicine (CN), Beijing Biocytogen (China) (CN), Hebei General Hospital (CN), Shijiazhuang Yiling Pharmaceutical (China) (CN)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Bioequivalence of a single dose of two palbociclib formulations in healthy Chinese subjects under fasting conditions: a two-period crossover study with rabeprazole pre-treatment — Bo Qiu, Shuo Shi, et al. · Frontiers in Pharmacology (2025) | TGRS Research Map | TGRS